Erste Group upgraded shares of biotechnology firm Amgen (NASDAQ:AMGN) from Hold to Buy. The upgrade was primarily attributed to Amgen's financial performance, which includes a higher operating margin ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...

Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North ...

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...